5.65 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||5.51 x 1300|
|Ask||6.40 x 1000|
|Day's Range||5.58 - 6.00|
|52 Week Range||4.42 - 11.35|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.17|
Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim basis. Dr. Pomerantz will continue as Chairman of Seres’ Board of Directors.
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
“Advancing SER-287 into a late stage Phase 2B trial is a significant achievement,” said Kevin Horgan, M.D., Executive Vice President and Chief Medical Officer. “We are hopeful that SER-287 may provide individuals with ulcerative colitis with a novel microbiome-based, non-immunosuppressive therapy that addresses the underlying pathology of this serious disease. The SER-287 Phase 2B ECO-RESET study has been designed as a pivotal trial.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer -
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Dr. Horgan will lead Seres’ clinical development, clinical operations, regulatory affairs, and medical affairs functions. Dr. Horgan will succeed Seres’ outgoing Chief Medical Officer, Michele Trucksis, Ph.D., M.D., who will continue to provide consulting services to the Company.
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection
WASHINGTON, Aug. 14, 2018 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) announced today the formation of their coalition which seeks to nurture innovation in microbiome therapeutics and microbiome-based products to address unmet medical needs and bring life-saving treatments to patients. The founding MTIG Board of Directors is comprised of Thomas J. DesRosier, Chairman of the MTIG Board and Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, Lee Jones, MTIG Secretary and Founder, President and Chief Executive Officer of Rebiotix Inc., and Bernat Olle, Co-founder and Chief Executive Officer of Vedanta Biosciences.
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 1.45% and -11.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Seres Therapeutics Inc (NASDAQ: MCRB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern Time. ...
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update.
Seres Therapeutics, Inc. today announced it will present at each of the following upcoming healthcare conferences:
Often, publicly-traded companies that trade in discount-bin valuations are there for a reason. When it becomes clear that success is no longer probable, astute investors bail, leaving others holding the bag.
Seres Therapeutics, Inc. today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY.